FDA Approves Expanded Indication for Merck’s KEYTRUDA (pembrolizumab) in Adult Patients With…
Merck, known as MSD outside the United States and Canada, announced that the U.S. Food and Drug Administration (FDA) has approved an expanded label for KEYTRUDA, Merck’s anti-PD-1…
Read More...
Read More...
